JGJan Jaap de Graeff

Jan Jaap de Graeff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jan Jaap de Graeff has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas M. van Gulik

    Department of Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands

    3 shared publications
  • Belle V. van Rosmalen

    Department of Surgery, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands

    2 shared publications
  • Belle V. van Rosmalen

    Department of Surgery, Academic Medical Centre, Amsterdam, the Netherlands

    2 shared publications
  • Joanne Verheij

    Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, the Netherlands; Department of Pathology, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands

    2 shared publications
  • Joanne Verheij

    Department of Pathology, UMC, University of Amsterdam, Cancer Center Amsterdam

    2 shared publications
  • Joris I. Erdmann

    Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

    2 shared publications

Latest Publications

  • Relief of symptoms and quality of life after conservative versus surgical treatment of benign liver tumors (CONSULT): a retrospective propensity score matched study

    by Alicia Furumaya, Belle V. van Rosmalen, Jan Jaap de Graeff, Marcel J. van der Poel, D. Sandjai Ramsoekh, Geert Kazemier, Joanne Verheij, R. Bart Takkenberg, Marc G. Besselink, Joris I. Erdmann, et al.


  • Open Access

    Systematic review on percutaneous aspiration and sclerotherapy versus surgery in symptomatic simple hepatic cysts

    by Alicia Furumaya, Belle V. van Rosmalen, Jan Jaap de Graeff, Martijn P.D. Haring, Vincent E. de Meijer, Thomas M. van Gulik, Joanne Verheij, Marc G. Besselink, Otto M. van Delden, Joris I. Erdmann


  • Impact of open and minimally invasive resection of symptomatic solid benign liver tumours on symptoms and quality of life: a systematic review

    by Belle V. van Rosmalen, Jan Jaap de Graeff, Marcel J. van der Poel, Ilja E. de Man, Marc Besselink, Mohammad Abu Hilal, Olivier R. Busch, Joanne Verheij, Thomas M. van Gulik


  • Open Access

    Safety and efficacy of transarterial embolization of hepatocellular adenomas

    by B V van Rosmalen, A J Klompenhouwer, J Jaap de Graeff, M P D Haring, V E de Meijer, L Rifai, S Dokmak, A Rawashdeh, M Abu Hilal, M C de Jong, et al.

    Background: Hepatocellular adenoma (HCA) larger than 5 cm in diameter has an increased risk of haemorrhage and malignant transformation, and is considered an indication for resection. As an alternative to resection, transarterial embolization (TAE) may play a role in prevention of complications of HCA, but its safety and efficacy are largely unknown. The aim of this study was to assess outcomes and postembolization effects of selective TAE in the management of HCA. Methods: This retrospective, multicentre cohort study included patients aged at least 18 years, diagnosed with HCA and treated with TAE. Patient characteristics, 30-day complications, tumour size before and after TAE, symptoms before and after TAE, and need for secondary interventions were analysed. Results: Overall, 59 patients with a median age of 33.5 years were included from six centres; 57 of the 59 patients were women. Median tumour size at time of TAE was 76 mm. Six of 59 patients (10 per cent) had a major complication (cyst formation or sepsis), which could be resolved with minimal therapy, but prolonged hospital stay. Thirty-four patients (58 per cent) were symptomatic at presentation. There were no significant differences in symptoms before TAE and symptoms evaluated in the short term (within 3 months) after TAE (P = 0·134). First follow-up imaging was performed a median of 5·5 months after TAE and showed a reduction in size to a median of 48 mm (P < 0·001). Conclusion: TAE is safe, can lead to adequate size reduction of HCA and, offers an alternative to resection in selected patients.


  • Closed reduction of congenital dislocation of the hip: prediction factors and results

    by Michal S. Galek-Aldridge, Jan Jaap de Graeff, Peter A.A. Struijs

    From 2009 to 2015, 15 infants with a congenital dislocation of the hip were treated with closed reduction under anaesthesia, after first being treated with Pavlik bandaging. A retrospective study was carried out with a minimum follow-up of 1 year to assess the success rate of the procedure and predictive factors. Twelve out of 15 (80%) patients achieved successful reduction. In the successful cases, the Barlow test was positive and the safe zone was 20° or more. In the unsuccessful cases, there was a negative Barlow present in the outpatient clinic and the safe zone was less than 20°. These three cases all had teratologic comorbidity, and required additional surgery in the form of open reduction. Avascular necrosis was noted in one out of 15 (6.7%) patients. In nonteratologic hips, a positive Barlow test with a safe zone of 20° is predictive of a successful closed reduction. In these patients, anaesthesia and arthrography might not be necessary.


  • Prognostic Factors for Failure of Antibiotic Treatment in Patients With Osteomyelitis of the Spine

    by Jan Jaap de Graeff, Nuno Rui Paulino Pereira, Olivier D. van Wulfften Palthe, Sandra B. Nelson, Joseph H. Schwab

    Study Design.: Retrospective cohort study. Objective.: The aim of this study was to identify factors independently associated with antibiotic treatment failure in patients with spinal osteomyelitis. Summary of Background Data.: There are few studies that have identified risk factors for antibiotic treatment failure in medically managed spinal osteomyelitis. Identifying such factors could help to identify patients who can be treated solely with antibiotics. Methods.: All patients who underwent antibiotic treatment for spinal osteomyelitis in one of our institutions between January 1, 2001 and January 1, 2015 were identified. Patients who underwent surgery before the start of the antibiotic treatment were excluded. Results.: We included 215 patients with a mean age of 58 years; 63 (29%) patients had failure of antibiotic treatment. Diabetes (hazard ratio [HR] 1.69, 95% confidence interval [CI] 1.03–2.79, P = 0.037), fever (HR 1.61, 95% CI 0.93–2.79, P = 0.088), osteomyelitis at an additional site (HR 5.17, 95% CI 2.63–27.9, P = 0.001), and the presence of an epidural abscess (HR 1.91, 95% CI 1.05–3.45, P = 0.033) were associated with failure of antibiotic treatment. In the multivariate Cox regression analysis, diabetes (HR 1.69, 95% CI 1.03–2.79, P = 0.019), osteomyelitis at an additional site (HR 8.26, 95% CI 2.51–27.2, P = 0.001), fever (HR 1.77, 95% CI 1.00–3.12, P = 0.050), and the presence of an epidural abscess (HR 1.82, 95% CI 1.06–3.13, P = 0.030) were independently associated with failure of antibiotic treatment. Conclusion.: Antibiotic treatment failed in 29% of patients; diabetes, current other osteomyelitis, and having an epidural abscess were independently associated with failure of antibiotic treatment. Level of Evidence: 3